Hematologic Malignancies Market

Hematologic Malignancies Market by Types (Lymphoma, Multiple Myeloma, and Leukemia [Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, and Acute Myeloid Leukemia], and Others), Therapies (Radiotherapy, Stem Cell Transplantation, Chemotherapy, Immunotherapy, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1429
  • Author: Growth Market Reports
  • Rating: 4.7
  • Total Reviews: 2
  • No. Of Pages: 183
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global hematologic malignancies market size is estimated to register a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing cases of blood cancer and the rise in developing of new treatments.

Hematologic Malignancies Market key Takeaways

Blood malignancy is the second most leading cause of cancer death and is the fifth most common cancer in the world. Lymph nodes, bone marrow, and blood are affected by blood malignancies. There are different forms such as lymphoma, leukemia, and myeloma. Hematological malignancies are treated by oncologists and hematologists. Lymphoid cell and myeloid are the two key blood cell lineages from where hematological malignancies can be derived. The lymphoid lineage includes lymphomas, leukemia, and myeloma, while the myeloid lineage consists of myelodysplastic syndromes, acute and chronic myelogenous leukemia, and myeloproliferative disorders. Hematological malignancies are also called as liquid tumors. Immunotherapy, chemotherapy, radiotherapy and bone marrow transplant are the effective treatments to cure hematologic malignancies.

As per Global Cancer Observatory, the number of registered cases of Leukemia and multiple myelomia globally are around 67,784 and 35,318 cases respectively. In December 2020, The Leukemia and Lymphoma Society (LLS), has initiated a collaboration with leading cancer institutions and foundations to invest nearly about USD 17 million research grants. This investment was aimed at advancement of research on effective treatment alternatives for patients suffering from leukemia, lymphoma, myeloma, and other blood cancers. Furthermore, in December 2020, Jazz Pharmaceuticals has submitted Biologics License Application for its JZP-458. It is used as a component of a multi-agent chemotherapy regimen for the treatment of patients suffering from acute lymphoblastic leukemia. Apart from this, government is also taking initiatives and encourage researchers to collaborate for developing advanced treatment and therapy.

Due to the COVID-19 pandemic outbreak, the hematologic malignancies treatment market is substantially impacted. However, all major precautions are taken to treat hematologic malignancies, followed by prescribed guidelines. Alternatively, patients are encouraged telemedicine consultation for follow-ups, and hospitals & clinics are minimizing the contacts between patients & staffs for the treatment. In addition, according to United Kingdom Coronavirus Cancer Monitoring Project (UKCCMP), 2020, patients with blood malignancies have a higher chance of severe COVID-19 infection, which was estimated to be around 57 percent. As a result of the aforementioned causes, the COVID-19 pandemic is predicted to have an impact on the market's growth.

Market Trends, Drivers, Restraints, and Opportunities

  • Development of pre-clinical and clinical research along with the advancement in therapeutics coupled with the presence of robust product pipeline are anticipated to drive market growth.
  • Rising geriatric population across the world is another factor of growing prevalence of blood cancer. This is expected to boost the market growth in the coming years.
  • Formation of new rules and regulations from government bodies encouraging for the development of new drugs for blood cancer are estimated to propel the hematologic malignancies market.
  • Increasing expenditures and high cost investment in the treatment process are likely to hamper the market growth.
  • Less awareness among the people related to different types of cancers is another key challenge that can hinder the market growth during the forecast period.
  • Increasing collaboration among key healthcare companies and research institutes to develop advanced therapies for hematologic malignancies, which is projected to expand the market growth during the forecast period.

Scope of the Report

The report on the global hematologic malignancies market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Hematologic Malignancies Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types (Lymphoma, Multiple Myeloma, Leukemia [Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, and Acute Myeloid Leukemia], and Others) and Therapies (Radiotherapy, Stem Cell Transplantation, Chemotherapy, Immunotherapy, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

GlaxoSmithKline PLC; Pfizer, Inc.; F. Hoffmann-LA; Johnson & Johnson Services, Inc.; Roche ltd; Sanofi-Aventis; Takeda Pharmaceutical Company Limited; Bristol-Myers Squibb Company; AbbVie, Inc.; Novartis AG; and Celgene Corporation.

 

Market Segment Insights

Leukemia is anticipated to represent a large market share

Based on types, the hematologic malignancies market is segregated into lymphoma, multiple myeloma, leukemia, and others. The leukemia segment is further segmented into chronic lymphocytic leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, and acute myeloid leukemia. The leukemia segment is anticipated to represent a large market share during the forecast period due to higher selling of the cancer treatment medications such as Imbruvica, Glivec, and Rituxan. They are most commercially successful oncology drugs present in the market worldwide. Within the segment, the acute myeloid leukemia segment is projected to exhibit a rapid growth rate during the forecast period 2021-2028 due to the presence of a strong product pipeline and its estimated commercialization across the globe.

Chemotherapy is expected to grow considerably in coming years

On the basis of therapy, the market is categorized into radiotherapy, stem cell transplantation, chemotherapy, immunotherapy, and others. The chemotherapy segment held a dominant market share in 2020 and is expected to grow considerably in the coming years as it is wide considered to be the first line of treatment for all types of cancer. For most types of blood cancer, chemotherapy is the most commonly adopted treatment and several specific drug or combination of drugs are used for the treatment of the cancer type. Meanwhile, the immunotherapy segment is estimated to register a substantial CAGR during the forecast period, attributing to the higher efficiency and lower adverse of the therapy type. Wide adoption of advanced technology and innovative developments of immunotherapy are projected to boost the segment growth.

Hematologic Malignancies Market by Therapy

North America is projected to constitute a key market share

In terms of regions, the global hematologic malignancies market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is projected to constitute a key market share during the forecast period. The regional market growth can be attributed to wide establishment of advanced healthcare infrastructure and availability of branded drugs. Moreover, factors such as high prevalence of blood cancer patients as well as presence of key global players in the region present another key aspects for the market growth in North America.

On the other hand, the market of Asia Pacific is estimated to expand at a substantial CAGR during the forecast period owing to increasing awareness of initial diagnosis and growing inclination towards healthcare expenditure among a large number of the population in the region. Furthermore, factors including high unmet clinical needs of patients and availability of effective treatment in emerging countries such as India and China are key drivers for the regional market growth.

Hematologic Malignancies Market by Regions

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hematologic Malignancies Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Hematologic Malignancies Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Hematologic Malignancies Market - Supply Chain
  4.5. Global Hematologic Malignancies Market Forecast
     4.5.1. Hematologic Malignancies Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Hematologic Malignancies Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Hematologic Malignancies Market Absolute $ Opportunity
5. Global Hematologic Malignancies Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Hematologic Malignancies Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Hematologic Malignancies Demand Share Forecast, 2019-2026
6. North America Hematologic Malignancies Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Hematologic Malignancies Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Hematologic Malignancies Demand Share Forecast, 2019-2026
7. Latin America Hematologic Malignancies Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Hematologic Malignancies Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Hematologic Malignancies Demand Share Forecast, 2019-2026
8. Europe Hematologic Malignancies Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Hematologic Malignancies Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Hematologic Malignancies Demand Share Forecast, 2019-2026
9. Asia Pacific Hematologic Malignancies Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Hematologic Malignancies Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Hematologic Malignancies Demand Share Forecast, 2019-2026
10. Middle East & Africa Hematologic Malignancies Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Hematologic Malignancies Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Hematologic Malignancies Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Hematologic Malignancies Market: Market Share Analysis
  11.2. Hematologic Malignancies Distributors and Customers
  11.3. Hematologic Malignancies Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)

Segments Covered in the Report
The global hematologic malignancies market has been segmented on the basis of

Types

  • Lymphoma
  • Multiple Myeloma
  • Leukemia
    • Chronic Lymphocytic Leukemia
    • Chronic Myeloid Leukemia
    • Acute Lymphocytic Leukemia
    • Acute Myeloid Leukemia
  • Others

Therapies

  • Radiotherapy
  • Stem Cell Transplantation
  • Chemotherapy
  • Immunotherapy
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • GlaxoSmithKline PLC
  • Pfizer, Inc.
  • F. Hoffmann-LA
  • Johnson & Johnson Services, Inc.
  • Roche ltd
  • Sanofi-Aventis
  • Takeda Pharmaceutical Company Limited
  • Bristol-Myers Squibb Company
  • AbbVie, Inc.
  • Novartis AG
  • Celgene Corporation

Some of the key players in the global hematologic malignancies market are GlaxoSmithKline PLC; Pfizer, Inc.; F. Hoffmann-LA; Johnson & Johnson Services, Inc.; Roche ltd; Sanofi-Aventis; Takeda Pharmaceutical Company Limited; Bristol-Myers Squibb Company; AbbVie, Inc.; Novartis AG; and Celgene Corporation.

Major players are trying to expand their businesses in developing regions to increase their market share. Furthermore, companies are adopting marketing strategies such as new product development, and mergers & acquisitions. For example, AbbVie, Inc. has acquired Pharmacyclics, Inc., a major global leader in the hematologic oncology market in March 2015. With this acquisition, they aimed at increasing their presence in scientific and commercial oncology.

Hematologic Malignancies Market by Key Players

Buy Report